Chair: P. Verginis
10:00-10:40 Immunosurveillance, Immunoediting and Immune escape J. Wiscchusen
10:40-11:20 Cancer immune escape mechanisms N. Aptsiauri
11:20-12:00 Immune suppression in cancer P. Verginis
Chair: J. Wiscchusen
12:30-13:10 Intracellular tumor antigen processing and immune checkpoint blockade E. Stratikos
13:10-13:50 Regulation of immune checkpoint blockade clinical outcomes by Immune and cancer gene signatures D. Speiser
Chair: A. Kotsakis
16:00-16:40 Current status of immunotherapy in NSCLC D. Papadatos-Pastos
16:40-17:20 Current status of immunotherapy in SCLC and Mesothelioma K. Leventakos
Chair: A. Kotsakis
Resistance to Immune checkpoint inhibition F. Skoulidis
Chair: E. Stratikos
18:30-19:10 Inflammation and cancer: a yin - yang affair A. Igea
19:10-19:50 Tumor microenvironment in solid tumors I. Pateras
19:50-20:30 The host-microbiome crosstalk and its impact on tumorigenesis T. Frisan
Chair: D. Mastellos
10:00-10:40 Cellular therapy (CAR T-cells) G. Vassilopoulos
10:40-11:20 Natural Killers for cancer immunotherapy A. Madrigal
Chair: O. Tsitsilonis
11:50-12:30 Cancer Vaccines Κ. Kosmatopoulos
12:30-13:10 Therapeutic targeting of the complement system D. Mastellos
Chair: O. Tsitsilonis
Chair: M. Koukourakis
15.30-16.10 Routine biomarkers in routine practice A. Giatromanolaki
16.10-16.50 Genomic Landscape of Response and Resistance to Immune Checkpoint Blockade V. Anagnοstou
16:50-17:30 HRD and immunotherapy M. Liontos
Chair: A. Giatromanolaki
17.30-18.10 The immunotherapy landscape for renal cell carcinoma F. Koinis
18.10-18.50 State of the art of immunotherapy in urothelial cancer P. Grivas
18.50-19.20 The current status of immunotherapy in GI tumors G. Papaxoinis
Chair: O. Tsitsilonis
10:00-10:40 miRNAs B. Seliger
10:40-11:20 Immune modulation for cancer treatment G. Adema
11:20-12:00 Anti-cancer immunity and aging G. Pawelec
Chair: G. Pawelec
12:30-13:10 State of the art of immunotherapy in malignant melanoma H. Gogas
13:10-13:50 Advances of immunotherapy in breast cancer D. Tryfonopoulos
13:50-14:30 The role of Cemiplimab in the management of advanced cutaneous squamous cell carcinoma I. Samaras
Sponsored By Sanofi Genzyme
Chair: Α. Kotsakis
15:30-16:10 Targeting Cancer with BiTE® Constructs R. Kischel
16:10-16:50 Emerging immunotherapy targets M. Karasarides
16:50-17:30 Therapeutic approach of immune adverse events A. Koumarianou
Meeting Wrap U